Agilent Technologies Inc., (A) Human Metabolome Technologies Collaborate On Metabolomics Solution To Speed Disease And Drug Research
10/19/2005 5:09:19 PM
TOKYO--(BUSINESS WIRE)--June 20, 2005--Agilent Technologies Inc. (NYSE:A) and Human Metabolome Technologies, a Japanese bioventure, today announced they have signed an agreement to collaborate on an integrated set of metabolome analysis tools designed to help researchers discover potential therapeutics.
Under the agreement, the two companies will work to integrate HMT's novel biochemical assays with Agilent's capillary electrophoresis (CE) and mass spectrometry (MS) technologies for the profiling, identification and quantitation of metabolic markers. Metabolomics, which aims to characterize the complete set of metabolites, provides critical insights into how living things function under particular conditions, such as stress or disease, and may help identify targets for drug development. Typical human cells contain thousands of metabolites, and the aim of the HMT/Agilent solution is to develop a new and unique mass-spectrometry-based workflow for high throughput analysis.